Skip to main navigation Skip to search Skip to main content

Quality prescribing in early psychosis: key pharmacotherapy principles

  • James G. Scott
  • , Gemma McKeon
  • , Eva Malacova
  • , Jackie Curtis
  • , Bjorn Burgher
  • , Iain Macmillan
  • , Andrew Thompson
  • , Stephen D. Parker

Research output: Contribution to journal › Article › Research › peer-review

Abstract

Objective: To present a practical, easy-to-implement clinical framework designed to support evidence-based quality prescribing for people with early psychosis. Method: Identification and explanation of key principles relating to evidence-based pharmacotherapy for people with early psychosis. These were derived from the literature, practice guidelines and clinical experience. Results: Key principles include (1) medication choice informed by adverse effects; (2) metabolic monitoring at baseline and at regular intervals; (3) comprehensive and regular medication risk–benefit assessment and psychoeducation; (4) early consideration of long-acting injectable formulations (preferably driven by informed patient choice); (5) identification and treatment of comorbid mood disorders and (6) early consideration of clozapine when treatment refractory criteria are met. Conclusions: Current prescribing practices do not align with the well-established evidence for quality pharmacotherapy in early psychosis. Adopting evidence-based prescribing practices for people with early psychosis will improve outcomes.

Original languageEnglish
Pages (from-to)341-345
Number of pages5
JournalAustralasian Psychiatry
Volume30
Issue number3
DOIs
Publication statusPublished - Jun 2022

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • antipsychotic medications
  • early psychosis
  • maintenance treatment
  • prescribing practices

Cite this